4 Things to Know About Cannabis Being Rescheduled to a Lesser Dangerous Drug
As the conversation around cannabis legalization progresses, the potential rescheduling of cannabis from a Schedule I drug is gaining attention across the United States. Rescheduling cannabis could bring monumental changes for the industry, consumers, and researchers. This shift would lower cannabis’ classification under the Controlled Substances Act (CSA), opening doors to broader medical and recreational use and enhanced research opportunities. Here are four key points to understand as cannabis moves closer to being reclassified.
1. Current Classification and Its Implications for Cannabis
Cannabis is currently listed as a Schedule I drug, which places it alongside substances like heroin and LSD. This classification means cannabis is deemed to have “no accepted medical use” and a “high potential for abuse.” This classification has significant consequences, as it severely restricts research, limits access to cannabis-based treatments, and creates challenges for businesses operating in states with legal cannabis markets.
However, with the majority of U.S. states allowing either medical or recreational cannabis, the Schedule I classification has become increasingly outdated. Many states, especially those with medical cannabis programs, have demonstrated the medical efficacy of cannabis in treating conditions like chronic pain, epilepsy, and anxiety, fueling the movement to reclassify cannabis at the federal level.
2. Rescheduling Could Have Different Impacts at State and Federal Levels
While federal rescheduling would be a major step forward, the impact on state-level cannabis laws would vary. States currently have their own laws regarding medical and recreational cannabis, with some allowing full legalization and others maintaining strict prohibitions.
In states like California, Colorado, and Oregon, which already have robust recreational and medical cannabis markets, federal rescheduling would simplify banking, interstate commerce, and even taxation. Federal reclassification could encourage more investment in cannabis businesses, allow easier access to financial services, and possibly pave the way for nationwide legalization in the long term.
However, states that have remained resistant to cannabis reform, such as Idaho and Nebraska, may continue to uphold their own prohibitions despite federal reclassification. Therefore, while rescheduling at the federal level would provide uniformity in some aspects, state laws would still play a significant role in determining how cannabis is regulated locally.
3. Public Support and Health Department Recommendations Are Driving Change
Public support for cannabis reform has grown significantly over the last decade. According to a 2023 Gallup poll, 68% of Americans support the legalization of cannabis for recreational use, while an overwhelming majority supports cannabis for medical purposes. This growing public approval has spurred action from both political leaders and regulatory agencies.
In August 2023, the Health and Human Services (HHS) made a landmark recommendation to the DEA to move cannabis from Schedule I to Schedule III, a category that includes substances like anabolic steroids and testosterone. Schedule III drugs are classified as having “moderate to low potential for physical and psychological dependence,” a significant shift from the current designation. This recommendation marks a pivotal moment in the cannabis reform movement, signaling that a lower schedule designation is on the horizon.
4. Rescheduling Would Enhance Medical Research and Business Opportunities
One of the most significant benefits of rescheduling cannabis would be the expansion of medical research. Under its current classification, obtaining federal approval for cannabis research is difficult. A lower scheduling would ease these restrictions, allowing scientists and pharmaceutical companies to conduct more studies on the medical benefits of cannabis. This would be particularly beneficial for studying the potential of cannabis to treat conditions such as epilepsy, PTSD, and multiple sclerosis.
Additionally, cannabis businesses could see significant growth, particularly in the areas of banking and investment opportunities. Currently, most cannabis businesses operate as cash-only enterprises because federal law prohibits banks from working with companies that deal with Schedule I drugs. A lower classification would allow cannabis companies to access banking services, secure loans, and expand more easily.
This shift would also foster job creation, as more businesses could enter the market and operate without the fear of federal interference.
What’s Next for Cannabis Rescheduling?
If cannabis is rescheduled to Schedule III or lower, it could mark a turning point in the cannabis industry. It would provide broader access to medical cannabis, promote more scientific research, and ease the restrictions that currently complicate financial transactions for cannabis businesses. This change would also pressure states with stricter cannabis laws to reconsider their policies.
As momentum for cannabis reform grows, rescheduling at the federal level could be the first step toward full federal legalization, with widespread benefits for medical research, businesses, and consumers alike.
Sources: